We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
+35.87%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$211M
AUM Growth
-$31.9M
(-13%)
Cap. Flow
-$83.2M
Cap. Flow
% of AUM
-39.42%
Top 10 Holdings %
Top 10 Hldgs %
8.5%
Holding
499
New
89
Increased
112
Reduced
218
Closed
57
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Delek Logistics
DKL
|
+$1.29M |
| 2 |
Western Midstream Partners
WES
|
+$970K |
| 3 |
Viper Energy
VNOM
|
+$883K |
| 4 |
Canadian Natural Resources
CNQ
|
+$761K |
| 5 |
EPR Properties
EPR
|
+$729K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Barings BDC
BBDC
|
+$2.49M |
| 2 |
Prospect Capital
PSEC
|
+$2.37M |
| 3 |
BKCC
BlackRock Capital Investment Corporation
BKCC
|
+$2.34M |
| 4 |
Nuveen Credit Strategies Income Fund
JQC
|
+$2.3M |
| 5 |
WhiteHorse Finance
WHF
|
+$2.12M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 33.94% |
| 2 | Real Estate | 15.9% |
| 3 | Energy | 15.5% |
| 4 | Materials | 8.79% |
| 5 | Financials | 7.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
226
Arvinas
ARVN
$529M
| $374K | 0.18% |
11,162
+2,700
| +32% | +$115K |
|
|
KYNB
227
Kyntra Bio
KYNB
$28.2M
| $372K | 0.18% |
367
+59
| +19% | +$54.8K |
|
228
Madrigal Pharmaceuticals
MDGL
$12.4B
| $372K | 0.18% |
3,287
-396
| -11% | -$38.9K |
|
229
Oaktree Specialty Lending
OCSL
$1.06B
| $372K | 0.18% |
27,769
-114,452
| -80% | -$1.42M |
|
|
MRNS
230
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $372K | 0.18% |
+36,640
| New | +$337K |
|
|
ALLK
231
DELISTED
Allakos
ALLK
| $371K | 0.18% |
5,159
+2,231
| +76% | +$149K |
|
232
Ascendis Pharma A/S
ASND
$16.7B
| $371K | 0.18% |
2,511
-606
| -19% | -$83.2K |
|
|
EFR
233
Eaton Vance Senior Floating-Rate Fund
EFR
$312M
| $371K | 0.18% |
32,798
-149,534
| -82% | -$1.62M |
|
234
Gossamer Bio
GOSS
$100M
| $371K | 0.18% |
28,554
+14,388
| +102% | +$181K |
|
235
Cartesian Therapeutics
RNAC
$225M
| $371K | 0.18% |
+4,357
| New | +$395K |
|
236
Allogene Therapeutics
ALLO
$573M
| $370K | 0.18% |
8,650
-4,629
| -35% | -$167K |
|
237
Zymeworks
ZYME
$1.66B
| $370K | 0.18% |
10,248
+1,691
| +20% | +$62.3K |
|
|
TPTX
238
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $370K | 0.18% |
5,728
-770
| -12% | -$44.4K |
|
|
APLS
239
DELISTED
Apellis Pharmaceuticals
APLS
| $369K | 0.17% |
11,299
-1,697
| -13% | -$54.5K |
|
240
Alaunos Therapeutics
TCRT
$4.64M
| $369K | 0.17% |
751
+265
| +55% | +$118K |
|
241
Ardelyx
ARDX
$1.25B
| $368K | 0.17% |
53,159
+1,800
| +4% | +$12.5K |
|
242
CytomX Therapeutics
CTMX
$701M
| $367K | 0.17% |
44,006
-6,220
| -12% | -$57.8K |
|
243
Regenxbio
RGNX
$615M
| $367K | 0.17% |
9,952
+1,716
| +21% | +$64K |
|
|
IMGN
244
DELISTED
Immunogen Inc
IMGN
| $367K | 0.17% |
79,795
-20,636
| -21% | -$87.8K |
|
245
Gladstone Investment Corp
GAIN
$655M
| $366K | 0.17% |
35,790
-145,344
| -80% | -$1.49M |
|
246
Xenon Pharmaceuticals
XENE
$6.28B
| $366K | 0.17% |
+29,170
| New | +$371K |
|
|
EIDX
247
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
| $366K | 0.17% |
7,669
+2,002
| +35% | +$93.1K |
|
248
Voyager Therapeutics
VYGR
$184M
| $364K | 0.17% |
28,874
+2,166
| +8% | +$25.2K |
|
249
Moderna
MRNA
$22.1B
| $363K | 0.17% |
5,660
-13,644
| -71% | -$747K |
|
|
CALA
250
DELISTED
Calithera Biosciences, Inc
CALA
| $362K | 0.17% |
+3,427
| New | +$407K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
RC
Virtus ETF Advisers's Q2 2020 Portfolio in Review
As of Q2 2020, Virtus ETF Advisers held 499 positions worth $211M, down 13% from $243M the previous quarter. Its ten largest holdings account for 8.5% of the portfolio.
Virtus ETF Advisers withdrew a net $83.2M in Q2 2020, closing 57 positions and reducing 218 holdings. Its most notable exit was Tallgrass Energy, LP Class A Shares, an estimated $1.22M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 34% of assets, up from 20% a quarter earlier, followed by Real Estate and Energy.
Against the trend, Virtus ETF Advisers opened a new position in Verastem worth $342K.
- Virtus ETF Advisers's largest Q2 2020 buy was Verastem: 16,584 shares worth $342K.
- Virtus ETF Advisers added most to Delek Logistics in Q2 2020, an estimated $1.29M increase.
- Virtus ETF Advisers's biggest Q2 2020 reduction was Barings BDC, cutting an estimated $2.49M.
- Virtus ETF Advisers fully exited Tallgrass Energy, LP Class A Shares in Q2 2020, selling an estimated $1.22M.
- Virtus ETF Advisers's ten largest holdings make up 8.5% of its $211M portfolio in Q2 2020.
- Virtus ETF Advisers opened 89 new positions and closed 57 in Q2 2020.
- Virtus ETF Advisers's portfolio value fell 13% quarter-over-quarter to $211M.
Based on Virtus ETF Advisers's 13F filing for Q2 2020, filed 5 Aug 2020.